Provectus Pharmaceuticals, Inc. (PVCT)
-OTC Markets 0.65 
0.02(2.86%) 9:49AM EDT
| Prev Close: | 0.63 |
|---|
| Open: | 0.65 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 3.50 |
|---|
| Beta: | 0.52 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - 0.65 |
|---|
| 52wk Range: | 0.43 - 0.99 |
|---|
| Volume: | 4,435 |
|---|
| Avg Vol (3m): | 161,720 |
|---|
| Market Cap: | 81.91M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.12 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Provectus Receives Patent Allowance from U.S. Patent and Trademark OfficeBusiness Wire(Wed, Jun 5)
- PROVECTUS PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Provectus Updates Shareholders in Its Annual CEO LetterBusiness Wire(Mon, May 13)
- PROVECTUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- PROVECTUS PHARMACEUTICALS INC Files SEC form 8-K, Unregistered Sale of Equity SecuritiesEDGAR Online(Thu, Apr 18)
- PV-10 Data Presented by Moffitt Cancer Center Researchers Examines Induction of Systemic Immune Response in Multiple Tumor TypesBusiness Wire(Wed, Apr 10)
- Provectus Presents Data on PV-10 Combination Therapy at American Association of Cancer Research Annual MeetingBusiness Wire(Wed, Apr 10)
- PV-10 Immunology Data Presented by Moffit Cancer Center Researchers at the American Association for Cancer Research Annual MeetingBusiness Wire(Mon, Apr 8)
- BUYINS.NET Issues Provectus Pharmaceuticals SqueezeTrigger ReportGlobeNewswire(Mon, Apr 1)
- Immunology Data on PV-10 to Be Presented at the American Association for Cancer Research Annual MeetingBusiness Wire(Thu, Mar 21)
- Data on Provectus's PV-10 to Be Presented at the HemOnc Today – Melanoma and Cutaneous Malignancies Conference on March 22, 2013Business Wire(Wed, Mar 20)
- PROVECTUS PHARMACEUTICALS INC Files SEC form 10-K, Annual ReportEDGAR Online(Thu, Mar 14)
- PROVECTUS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of EqEDGAR Online(Thu, Feb 28)
- Provectus Pharmaceuticals Shares Are Trading on the OTCQBBusiness Wire(Fri, Jan 25)
- Provectus Pharmaceuticals Launches Free Mobile Investor Relations ApplicationBusiness Wire(Thu, Jan 24)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.12 |
|---|
| Quarterly EPS Est
(Mar-13)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | -0.05 |
|---|
Business Summary
Provectus Pharmaceuticals, Inc., a development-stage pharmaceutical company, engages in developing pharmaceuticals for oncology and dermatology indications.
View More